LON:N4PN4 Pharma Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding N4 Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 4.90 0.00 (0.00 %) (As of 06/3/2020 05:49 AM ET) Add Compare Share Today's Range 4.80Now: GBX 4.90▼ 4.9050-Day Range 4.75MA: GBX 5.74▼ 7.2052-Week Range 2Now: GBX 4.90▼ 7.90Volume324,369 shsAverage Volume1.76 million shsMarket Capitalization£7.46 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system. N4 Pharma Plc is based in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for N4 Pharma. Previous Next 2.4 Community Rank Outperform VotesN4 Pharma has received 103 “outperform” votes. (Add your “outperform” vote.)Underperform VotesN4 Pharma has received 109 “underperform” votes. (Add your “underperform” vote.)Community SentimentN4 Pharma has received 51.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about N4 Pharma and other stocks. Vote “Outperform” if you believe N4P will outperform the S&P 500 over the long term. Vote “Underperform” if you believe N4P will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldN4 Pharma does not currently pay a dividend.Dividend GrowthN4 Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, N4 Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of N4 Pharma is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of N4 Pharma is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioN4 Pharma has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:N4P Previous Symbol CUSIPN/A CIKN/A Webwww.n4pharma.com Phone+44-1332-690061Debt Debt-to-Equity Ratio1.62 Current Ratio13.71 Quick Ratio13.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£23,524.00 Price / Sales316.95 Cash FlowGBX 0.91 per share Price / Cash Flow5.37 Book ValueGBX 1 per share Price / Book4.90Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees5 Outstanding Shares152,194,000Market Cap£7.46 million Next Earnings DateN/A OptionableNot Optionable LSE:N4P Rates by TradingView Receive N4P News and Ratings via Email Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. N4 Pharma (LON:N4P) Frequently Asked Questions How has N4 Pharma's stock been impacted by COVID-19 (Coronavirus)? N4 Pharma's stock was trading at GBX 2.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, N4P shares have increased by 78.1% and is now trading at GBX 4.90. View which stocks have been most impacted by Coronavirus. How were N4 Pharma's earnings last quarter? N4 Pharma PLC (LON:N4P) released its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.87) earnings per share (EPS) for the quarter. View N4 Pharma's earnings history. Has N4 Pharma been receiving favorable news coverage? Media coverage about N4P stock has trended very negative on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. N4 Pharma earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutN4 Pharma. Who are some of N4 Pharma's key competitors? Some companies that are related to N4 Pharma include China Pharma (CPHI), Patrys (PAB), Cathay International (CTI), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF), OTSUKA HOLDINGS/ADR (OTSKY), Roche (RHHVF), Sanofi (SNYNF), Sanofi (SAN) and SINR PHAR/PAR VTG FPD 0.01 (SPH). View all competitors. What other stocks do shareholders of N4 Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Intercede Group (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Petra Diamonds (PDL), Interserve (IRV), Cornerstone Capital Resources (CGP) and Bushveld Minerals (BMN). Who are N4 Pharma's key executives? N4 Pharma's management team includes the following people: Mr. Nigel James Theobald, Founder & CEO (Age 55)Mr. Paul Titley, Exec. DirectorDr. Andrew Leishman, Consultant What is N4 Pharma's stock symbol? N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P." How do I buy shares of N4 Pharma? Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is N4 Pharma's stock price today? One share of N4P stock can currently be purchased for approximately GBX 4.90. How big of a company is N4 Pharma? N4 Pharma has a market capitalization of £7.46 million and generates £23,524.00 in revenue each year. N4 Pharma employs 5 workers across the globe. What is N4 Pharma's official website? The official website for N4 Pharma is www.n4pharma.com. How can I contact N4 Pharma? N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061. This page was last updated on 6/3/2020 by MarketBeat.com Staff
